Overview
- Plaintiff firms have filed or are soliciting shareholders to join a class action over Erasca stock bought between January 14, 2025 and April 26, 2026 and they must move for lead plaintiff by August 10, 2026.
- The litigation alleges Erasca and certain executives made misleading statements about ERAS‑0015’s preclinical comparisons, safety record and intellectual property, claims that investors say inflated the stock.
- On April 27–28, 2026 Erasca disclosed a letter from Revolution Medicines alleging patent infringement and trade‑secret misappropriation and reported adverse Phase 1 data including a trial‑related patient death, which the complaints say triggered a steep share decline.
- Erasca has told investors it believes Revolution Medicines’ assertions are without merit and intends to contest them, while law firms note the alleged misstatements occurred as the company raised new capital.
- If appointed, a lead plaintiff will direct the case and any recovery; investors who bought during the class period are not represented by counsel unless they retain one and can contact firms for contingency-fee representation.